3-year update on the ELOQUENT-2 clinical trial of elotuzumab in multiple myeloma - 101793

Spotlight
Video

3-year update on the ELOQUENT-2 clinical trial of elotuzumab in multiple myeloma

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the 3-year update presented at the American Society of Hematology (ASH) 2015 Annual Meeting, on the ELOQUENT-2 clinical trial of elotuzumab in combination with lenalidomide and dex­a­meth­a­sone in multiple myeloma. The study demonstrated a sustained progression-free survival (PFS) benefit to patients in the elotuzumab arm, when compared to placebo in relapsed/refractory myeloma.
Shared By : VJHemOnc
Posted on : 02/11/16
Added : 3 years ago
Category : Multiple Myeloma